3 Best Stocks to Buy Now, 4/24/2024, According to Top Analysts
Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
Biohaven Announces Pricing of $230 Million Public Offering of Common Shares
Maintaining Buy Rating: Biohaven’s BHV-1300 Shows Promising Efficacy and Safety Profile
Biohaven Announces Proposed Public Offering of Common Shares
Analysts Offer Insights on Healthcare Companies: Biohaven Ltd. (BHVN), Zoetis (ZTS) and Ginkgo Bioworks Holdings (DNA)
Buy Rating Affirmed for Biohaven Ltd. Amid Positive Clinical Outlook and Pipeline Potential
Biohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting and Provides Other Business Updates
Analysts Are Bullish on These Healthcare Stocks: Inozyme Pharma (INZY), Moderna (MRNA)
LLY, REGN, BHVN: Which Biotech Stock Offers the Most Upside?
Bullish Biohaven Insiders Loaded Up On US$23.8m Of Stock
Buy Rating Affirmed: Biohaven’s Innovative Pipeline and Financial Health Signal Promising Future
Buy Rating Affirmed: Biohaven Ltd. Poised for Key Milestones with Diverse Portfolio and Promising Lead Molecule BHV-7000
Buy Rating Affirmed for Biohaven Ltd. on Strong Pipeline and Upcoming Drug Advancements
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.